A recombinant attenuated Mycobacterium tuberculosis vaccine strain is safe in immunosuppressed simian immunodeficiency virus-infected infant macaques

Clinical and Vaccine Immunology

Volumn 19, Issue 8, 2012, Pages 1170-1181

  Jensen, Kara ^a   Ranganathan, Uma Devi K ^b   Van Rompay, Koen K A ^c   Canfield, Don R ^c   Khan, Imran ^d   Ravindran, Resmi ^d   Luciw, Paul A ^d   Jacobs, William R ^b   Fennelly, Glenn ^b   Larsen, Michelle H ^b   Abel, Kristina ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; LIVE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CONTROLLED STUDY; DRUG SAFETY; HISTOPATHOLOGY; MACACA; MICROBIAL ATTENUATION; MYCOBACTERIUM TUBERCULOSIS; NEWBORN; NONHUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; STRAIN DIFFERENCE; TUBERCULOSIS; VIRUS STRAIN;

EID: 84864572318     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00184-12     Document Type: Article

References (49)

1. Abel K. 2009. The rhesus macaque pediatric SIV infection model - a valuable tool in understanding infant HIV-1 pathogenesis and for designing pediatric HIV-1 prevention strategies. Curr. HIV Res. 7:2-11.
2. Abel K, et al. 2006. Rapid virus dissemination in infant macaques after oral simian immunodeficiency virus exposure in the presence of local innate immune responses. J. Virol. 80:6357-6367. (Pubitemid 43927439)
3. Amedee AM, Lacour N, Ratterree M. 2003. Mother-to-infant transmission of SIV via breast-feeding in rhesus macaques. J. Med. Primatol. 32:187-193. (Pubitemid 37021243)
4. Amedee AM, Rychert J, Lacour N, Fresh L, Ratterree M. 2004. Viral and immunological factors associated with breast milk transmission of SIV in rhesus macaques. Retrovirology 1:17.
5. Baena A, Porcelli SA. 2009. Evasion and subversion of antigen presentation by Mycobacterium tuberculosis. Tissue Antigens 74:189-204.
6. Brandtzaeg P. 1999. Regionalized immune function of tonsils and adenoids. Immunol. Today 20:383-384. (Pubitemid 29356433)
7. Cline AN, Bess JW, Piatak M, Jr, Lifson JD. 2005. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol. 34:303-312. (Pubitemid 41179592)
8. Colditz GA, et al. 1994. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. JAMA 271:698-702. (Pubitemid 24061706)
9. Croix DA, et al. 2000. Effect of mycobacterial infection on virus loads and disease progression in simian immunodeficiency virus-infected rhesus monkeys. AIDS Res. Hum. Retroviruses 16:1895-1908.
10. Freeman LM, et al. 2004. Body-composition changes in the simian immunodeficiency virus-infected juvenile rhesus macaque. J. Infect. Dis. 189:2010-2015. (Pubitemid 38692280)
11. Gill WP, et al. 2009. A replication clock for Mycobacterium tuberculosis. Nat. Med. 15:211-214.
12. Hesseling AC, et al. 2009. Disseminated bacille Calmette-Guérin disease in HIV-infected South African infants. Bull. World Health Organ. 87:505-511.
13. Hesseling AC, et al. 2007. The risk of disseminated bacille Calmette-Guérin (BCG) disease in HIV-infected children. Vaccine 25:14-18. (Pubitemid 44855247)
14. Hesseling AC, et al. 2006. Bacille Calmette-Guérin vaccine-induced disease in HIV-infected and HIV-uninfected children. Clin. Infect. Dis. 42:548-558. (Pubitemid 43202529)
15. Hinchey J, et al. 2007. Enhanced priming of adaptive immunity by a proapoptotic mutant of Mycobacterium tuberculosis. J. Clin. Invest. 117:2279-2288. (Pubitemid 47219573)
16. Jacobs M, Fick L, Allie N, Brown N, Ryffel B. 2002. Enhanced immune response in Mycobacterium bovis bacille Calmette Guérin (BCG)-infected IL-10-deficient mice. Clin. Chem. Lab. Med. 40:893-902. (Pubitemid 35277415)
17. Khan IH, et al. 2008. Profiling antibodies to Mycobacterium tuberculosis by multiplex microbead suspension arrays for serodiagnosis of tuberculosis. Clin. Vaccine Immunol. 15:433-438. (Pubitemid 351967073)
18. Lagranderie M, Chavarot P, Balazuc AM, Marchal G. 2000. Immunogenicity and protective capacity of Mycobacterium bovis BCG after oral or intragastric administration in mice. Vaccine 18:1186-1195. (Pubitemid 30001832)
19. Larsen MH, et al. 2009. Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates. Vaccine 27:4709-4717.
20. Lin PL, Flynn JL. 2010. Understanding latent tuberculosis: a moving target. J. Immunol. 185:15-22.
21. Luciw PA, et al. 2011. Stereological analysis of bacterial load and lung lesions in nonhuman primates (rhesus macaques) experimentally infected with Mycobacterium tuberculosis. Am. J. Physiol. Lung Cell. Mol. Physiol. 301:L731-L738.
22. Marchant A, et al. 1999. Newborns develop a Th1-type immune response to Mycobacterium bovis bacillus Calmette-Guérin vaccination. J. Immunol. 163:2249-2255. (Pubitemid 29382234)
23. Marthas ML, et al. 2011. Partial efficacy of a VSV-SIV/MVA-SIV vaccine regimen against oral SIV challenge in infant macaques. Vaccine 29:3124-3137.
24. Marthas ML, et al. 1995. Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques. J. Virol. 69:4198-4205.
25. Murray RA, et al. 2006. Bacillus Calmette Guérin vaccination of human newborns induces a specific, functionalCD8+ T cell response. J. Immunol. 177:5647-5651. (Pubitemid 44527640)
26. Neutra MR, Kozlowski PA. 2006. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol. 6:148-158. (Pubitemid 43361590)
27. Ota MO, et al. 2002. Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J. Immunol. 168:919-925. (Pubitemid 34049596)
28. 8+ T cell responses against human immunodeficiency virus type 1 Env and M. tuberculosis in neonatal mice. Vaccine 28:152-161.
29. Rodrigues LC, Diwan VK, Wheeler JG. 1993. Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis. Int. J. Epidemiol. 22:1154-1158. (Pubitemid 24025695)
30. Sambandamurthy VK, et al. 2006. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent andimmunocompromisedmice against experimental tuberculosis. Vaccine 24:6309-6320. (Pubitemid 44247236)
31. Sambandamurthy VK, et al. 2005. Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis. Infect. Immun. 73:1196-1203. (Pubitemid 40165781)
32. Sambandamurthy VK, Jacobs WR, Jr. 2005. Live attenuated mutants of Mycobacterium tuberculosis as candidate vaccines against tuberculosis. Microbes Infect. 7:955-961. (Pubitemid 40826665)
33. Sambandamurthy VK, et al. 2002. A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis. Nat. Med. 8:1171-1174. (Pubitemid 35175974)
34. Sampson SL, et al. 2011. Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate. Vaccine 29:4839-4847.
35. Shen Y, et al. 2001. Antiretroviral agents restore Mycobacterium-specific T-cell immune responses and facilitate controlling a fatal tuberculosis-like disease in macaques coinfected with simian immunodeficiency virus and Mycobacterium bovis BCG. J. Virol. 75:8690-8696. (Pubitemid 32768973)
36. Trunz BB, Fine P, Dye C. 2006. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367:1173-1180.
37. Van Rompay KK, et al. 2010. Immunogenicity of viral vector, prime-boost SIV vaccine regimens in infant rhesus macaques: attenuated vesicular stomatitis virus (VSV) and modified vaccinia Ankara (MVA) recombinant SIV vaccines compared to live-attenuated SIV. Vaccine 28:1481-1492.
38. Van Rompay KK, et al. 2003. Immunization of newborn rhesus macaques with simian immunodeficiency virus (SIV) vaccines prolongs survival after oral challenge with virulent SIVmac251. J. Virol. 77:179-190. (Pubitemid 36004958)
39. Van Rompay KK, et al. 1992. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3=-azido-3=-deoxythymidine prevents SIV infection. Antimicrob. Agents Chemother. 36:2381-2386.
40. Van Rompay KK, et al. 2004. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunologic parameters. J. Acquir. Immune Defic. Syndr. 36:900-914. (Pubitemid 38944085)
41. Vekemans J, et al. 2001. Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia. Infect. Immun. 69:6554-6557. (Pubitemid 32885227)
42. Waters WR, et al. 2009. Efficacy and immunogenicity of Mycobacterium bovis DeltaRD1 against aerosol M. bovis infection in neonatal calves. Vaccine 27:1201-1209.
43. WHO. 2011. Report on the global HIV/AIDS response. World Health Organization, Geneva, Switzerland. http://www.who.int/hiv/en/.
44. WHO. 2011. Global tuberculosis control 2011. World Health Organization, Geneva, Switzerland. http://www.who.int/tb/publications/global-report/en/.
45. WHO. 2011. World Health Organization HIV/TB facts 2011. World Health Organization, Geneva, Switzerland. http://www.who.int/hiv/topics/tb/hiv-tb- factsheet-june-2011.pdf.
46. WHO. 2007. Meeting of the immunization strategic advisory group of experts, April 2007 - conclusions and recommendations. Revised BCG vaccination guidelines for infants at risk for HIV infection. International Health Regulations. Wkly. Epidemiol. Rec. 82:181-196.
47. Wiseman CA, et al. 2012. A proposed comprehensive classification of tuberculosis disease severity in children. Pediatr. Infect. Dis. J. 31:347-352.
48. Zhou D, et al. 1999. Mycobacterium bovis bacille Calmette-Guérin enhances pathogenicity of simian immunodeficiency virus infection and accelerates progression to AIDS in macaques: a role of persistent T cell activation in AIDS pathogenesis. J. Immunol. 162:2204-2216. (Pubitemid 29288843)
49. Zimmerman DM, et al. 2009. Safety and immunogenicity of the Mycobacterium tuberculosis DeltalysA DeltapanCD vaccine in domestic cats infected with feline immunodeficiency virus. Clin. Vaccine Immunol. 16:427-429.